Moderna stock jumps 120% after cancer vaccine trial win: What investors need to know
Moderna stock surged after its mRNA cancer vaccine showed positive Phase 3 results with Merck’s Keytruda, boosting hopes for a new melanoma treatment.
5News aggregated this summary from the outlet’s public feed. The full article, with all the context, is on www.hindustantimes.com — the content belongs to Hindustan Times - World.